ストックスクリーナーアプリを入手
4.87
7.74%
0.35
Intensity Therapeutics Inc (INTS) 最新ニュース
INTS SEC FilingsINTENSITY THERAPEUTICS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Why Did INTS Stock Plummet 25% Today? - Stocktwits
Form 4 Intensity Therapeutics Inc For: 1 July By Investing.com - Investing.com Canada
ESPP purchase adds shares for Intensity Therapeutics (NASDAQ: INTS) officer - Stock Titan
Intensity Therapeutics (INTS) CFO adds 1,093 ESPP shares at discount - Stock Titan
Intensity Therapeutics updates INT230-6 cancer trials - grafa.com
Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6 - PR Newswire
Price to sales forward of Intensity Therapeutics, Inc. – NASDAQ:INTS - TradingView
Price to earnings forward of Intensity Therapeutics, Inc. – NASDAQ:INTS - TradingView
Enterprise value to EBITDA forward of Intensity Therapeutics, Inc. – NASDAQ:INTS - TradingView
Intensity Therapeutics, Inc. Actuals & Estimates (NASDAQ:INTS) - TradingView
Enterprise value to revenue forward of Intensity Therapeutics, Inc. – NASDAQ:INTS - TradingView
INTS Forecast — Price Target — Prediction for 2027 - TradingView
Intensity Therapeutics Inc (INTS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Intensity Therapeutics Inc (INTS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Intensity Therapeutics Inc (INTS) Institutional Confidence - TradingKey
Intensity Therapeutics Inc (INTS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Intensity Therapeutics Inc (INTS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Intensity Therapeutics Inc (INTS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Intensity Therapeutics Stockholders Approve Proposals at Annual Meeting - The Globe and Mail
Intensity Therapeutics Inc (INTS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Intensity Therapeutics Inc (INTS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Intensity Therapeutics Inc (INTS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Intensity Therapeutics shareholders approve board proposals at annual meeting By Investing.com - Investing.com Nigeria
Intensity Therapeutics shareholders approve board proposals at annual meeting - Investing.com
Intensity Therapeutics (NASDAQ: INTS) OKs share plan increases and board elections - Stock Titan
INTS: All proposals, including director elections and stock plan amendments, were approved by majority vote - TradingView
INTS Q1 2026 Earnings: Narrower-than-Expected Loss Surprises as Clinical Progress ContinuesROE Trend Analysis - dars.gov.et
Intensity Therapeutics (INTS) Shows Modest Decline, Holds Above Key SupportBear Flag - newsline.com
Intensity Therapeutics (INTS) Edges Lower as Stock Holds Near Key SupportIchimoku Kumo Break - newsline.com
Intensity_Therapeutics - Westfair Communications
Intensity Therapeutics (INTS) Slips 5.75% as Selling Pressure Intensifies Near Key Support LevelValue Stock Ideas - newsline.com
Intensity Therapeutics Inc (INTS) Stock Price, Quote, News & History - Benzinga
INTS News | INTENSITY THERAPEUTICS INC (NASDAQ:INTS) - ChartMill
INTS Technical Analysis | Trend, Signals & Chart Patterns | INTENSITY THERAPEUTICS INC (NASDAQ:INTS) - ChartMill
Intensity Therapeutics Inc. (INTS) upgraded to buy: Here's why - MSN
INTSIntensity Therapeutics Inc Short Interest - Finviz
INTS | Intensity Therapeutics, Inc. Common Insider Trading - Quiver Quantitative
INTS Q1 2026 Earnings: Narrower-Than-Expected Loss as Pre-Revenue Biotech Advances Clinical PipelineEPS Surprise History - The Legal Advocate
Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's Why - Yahoo Finance
INTS Q1 2026 Earnings: EPS Beat Despite Pre-Revenue Status; Shares Edge HigherRevenue Inflection Point - The Legal Advocate
Intensity Therapeutics Inc. (INTS) upgraded to buy: Here's what you should know - MSN
INTS Stock Price, Quote & Chart | INTENSITY THERAPEUTICS INC (NASDAQ:INTS) - ChartMill
Benchmark reiterates Intensity Therapeutics stock rating on clinical progress By Investing.com - Investing.com South Africa
Benchmark reiterates Intensity Therapeutics stock rating on clinical progress - Investing.com India
Intensity Therapeutics shares plunge 30% after $4 million discounted stock offering - MSN
Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award - ChartMill
Intensity Therapeutics Inc. (INTS) could find a support soon, here's why you should buy the stock now - MSN
How Intensity (INTS) maintains its competitive edge | Q4 2025: Earnings UnderperformMomentum Pick - Newser
Dyne Therapeutics (DYN) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
1.98%
3.59%
大文字化:
|
ボリューム (24 時間):